An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development

Molecular and Cellular Biochemistry

Volumn 176, Issue 1-2, 1997, Pages 61-71

  Buttar, Harpal S ^a  

^a Bureau of Drug Research   (Canada)

Author keywords

ACE inhibitors; Angiotensin converting enzyme inhibitors; Capozide; Developmental toxicity; Fetopathy; Oligohydramnios

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; BENAZEPRIL; CAPTOPRIL; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; GLUCOSE; HYDROCHLOROTHIAZIDE; LISINOPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANURIA; BABOON; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; ESSENTIAL HYPERTENSION; FETOTOXICITY; FETUS; FETUS CIRCULATION; FETUS DEATH; FETUS DISEASE; GLUCOSE BLOOD LEVEL; HEART DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; INTRAUTERINE GROWTH RETARDATION; ISCHEMIA; KIDNEY MALFORMATION; LUNG HYPOPLASIA; NEWBORN; NEWBORN DEATH; NONHUMAN; OLIGOHYDRAMNIOS; ORAL DRUG ADMINISTRATION; PATENT DUCTUS ARTERIOSUS; PERINATAL DEVELOPMENT; PERINATAL MORTALITY; PLACENTAL TRANSFER; PROTEIN PROCESSING; RABBIT; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SHEEP; SIDE EFFECT; SKULL MALFORMATION; SODIUM BALANCE;

AMNIOTIC FLUID; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; DRUG COMBINATIONS; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; FETUS; HUMANS; HYDROCHLOROTHIAZIDE; KIDNEY; PLACENTAL CIRCULATION; PREGNANCY; RABBITS; RATS; RENIN-ANGIOTENSIN SYSTEM;

ANIMALIA; ORYCTOLAGUS CUNICULUS; OVIS ARIES; PAPIO; PAPIO HAMADRYAS;

EID: 0030729396     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006822911586     Document Type: Review

References (58)

1. Poisner AM, Dowing GJ: Renin-angiotensin system in placenta. In: BV Rama Sastry (ed). Placental Toxicology. CRC Press, Boca Raton, 1995, pp. 175-196
2. Ehlers MW, Riordan JF: Angiotensin-converting enzyme: New concepts concerning its biological role. Biochemistry 28: 5311-5316, 1989
3. Jackson EK, Garrison JC: Renin and angiotensin. In: JG Hardman, LE Limbird, PB Molinoff, RW Ruddon, AG Gilman (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. McGraw-Hill, New York, 1996, pp. 733-758
4. Yosipiv IV, Dipp S, Eldahr SS: Ontogeny of somatic angiotensin-converting enzyme. Hypertension, 23: 369-374, 1994
5. Jelinek J, Hackenthal R, Hilgenfeldt U, Schaechtelin G, Hackenthal E: The renin-angiotensin system in the perinatal period in rats. J Dev Physiol 8: 33-41, 1986
6. Binder ND, Anderson DF: Plasma renin activity responses to graded decreases in renal perfusion pressure in fetal and newborn lambs. Am J Physiol 262: R524-R259, 1992
7. 1A receptor activates transcription factor Stat91 and/or arelatedprotein. J Biol Chem 269: 31443-31449, 1994
8. Materson BJ, Preston RA: Angiotensin-converting enzyme inhibitors in hypertension. Arch Int Med 154: 513-523, 1994
9. Williams GH: Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med 319: 1517-1524, 1988
10. Garay R, Senn N, Ollivier JP: Erythrocyte ion transport as indicator of sensitivity to antihypertensive drugs. Am J Med Sci 307 (Suppl. 1): S120-S125, 1994
11. Gavras H: The place of angiotensin-converting enzyme inhibitors in the treatment of cardiovascular diseases. N Engl J Med 319: 1541-1543, 1988
12. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type-II diabetic patients. Ann Int Med 118: 577-581, 1993
13. Bakris GL: Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Int Med 118: 643-644, 1993
14. Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes-mellitus and microalbuminuria. JAMA 271: 275-279, 1994
15. Mak IT, Freedman AM, Dickens BF, Weglicki WB : Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 40: 2169-2175, 1990
16. Westlin W, Mullane K: Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals. Circulation 77 (Suppl. 6): 130-139, 1988
17. Guthrie R: Fosinopril: An overview. Am J Cardiol 72: H22-H24, 1993
18. Piper JM, Ray WA, Rosa FW: Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol 80: 429-432, 1992
19. Endo M, Yamada Y, Kohno M, Suzuki T, Otsuka M, Takaiti O: Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. IV. Placental transfer and secretion into milk in rats. Arz Forsch/Drug Res 42: 483-489, 1992
20. Schubiger G, Flury G, Nussberger J: Enalapril for pregnancy-induced hypertension: acute renal failure in the neonate. Ann Int Med 108: 215-216, 1988
21. Pryde PG, Sedman AB, Nugent CE, Barr M: Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 3: 1575-1582, 1993
22. Barr M Jr: Teratogen update: Angiotensin-converting enzyme inhibitors. Teratology 50: 399-409, 1994
23. Food and Drug Administration. Dangers of ACE inhibitors during second and third trimesters of pregnancy. Med Bull 22: 2, 1992
24. Health Canada. Bureau of Drug Surveillance, Adverse Drug Reaction Monitoring Division, Drugs Directorate, Health Protection Branch, Ottawa, 1996
25. Barr M Jr, Cohen MM: ACE inhibitor fetopathy and hypocalvaria: The kidney-skull connection. Teratology 44: 485-495, 1991
26. Brent RL, Beckman DA: Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: Information for clinical teratology counselors. Teratology 43: 543-546, 1991
27. Knott PD, Thorp SS, Lamont CAR: Congenital renal dysgenesis possibly due to captopril. Lancet 1: 451, 1989
28. Cunniff C, Jones KL, Phillipson K, Short S, Wujek J: Oligohydramnios and renal tubular malformation associated with maternal enalapril use. Am J Obstet Gynecol 162: 187-189, 1990
29. Martin RA, Jones KL, Mendoza A, Barr M, Benirschke K: Effect of ACE inhibition on the fetal kidney: Decreased renal blood flow. Teratology 46: 317-321, 1992
30. Rosa FW, Bosco LA, Fossum-Graham C, Milstien JB, Dreis M, Creamer J: Neonatal anuria with maternal angiotensin-converting enzyme inhibition. Obstet Gynecol 74: 371-374, 1989
31. Robillard JE, Nakamura KT, Matherne GP, Jose PA: Renal hemodynamics and functional adjustments to postnatal life. Semin Perinatol 12: 143-150, 1988
32. Guignard JP, Gouyon JB: Adverse effects of drugs on the immature kidney. Biol Neonate 53: 243-252, 1988
33. Kalow W, Bertilsson L: Interethnic factors affecting drug response. In: B Testa, UA Meyer (eds). Advances in Drug Research, Vol. 25. Academic Press, New York, 1994, pp. 1-53
34. Bauer JH, Reams GP: Antihypertensive drugs. In: BM Brenner (ed). Brenner and Rector's The Kidney, Vol. 2., 5th ed. W.B. Saunders Company, Philadelphia, 1996, pp. 2331-2381
35. Broughton-Pipkin F, Symonds EM, Turner SR: The effect of captopril (SQ 14,225) upon mother and fetus in the chronically cannulated ewe and in the pregnant rabbit. J Physiol 323: 415-422, 1982
36. Lumbers ER, Kingsford NM, Menzies RI, Stevens AD: Acute effects of captopril, an angiotensin-converting enzyme inhibitor, on the pregnant ewe and fetus. Am J Physiol (Regulatory Integrative Comp Physiol) 262: R754-R760, 1992
37. Binder ND, Faber JJ: Effects of captopril on blood pressure, placental blood flow and uterine oxygen consumption in pregnant rabbits. J Pharmacol Exp Ther 260: 294-299, 1992
38. Harewood WJ, Phippard AF, Duggin GG, Horvath JS, Tiller DJ: Fetotoxicity of angiotensin-converting enzyme inhibition in primate pregnancy: A prospective, placebo-controlled study in baboons (Papio hamadryas). Am J Obstet Gynecol 171: 633-642, 1994
39. Al-Shabanah OA, Al-Harbi MM, Al-Gharably MA, Islam MW: The effect of maternal administration of captopril on fetal development in rat. Res Commun Chem Pathol Pharmacol 73: 221-230, 1991
40. Valdés G, Marinovic D, Falcón C, Chuaqui R, Duarte I: Placental alterations, intrauterine growth retardation and teratogenicity associated with enalapril use in pregnant rats. Biol. Neonate 61: 124-130, 1992
41. Minsker DH, Bagdon WJ, MacDonald JS, Robertson RT, Bokelman DL: Maternotoxicity and fetotoxicity of an angiotensin-converting enzyme inhibitor, enalapril, in rabbits. Fundam Appl Toxiol 14: 461-470, 1990
42. Dostal LA, Kim SN, Schardein JL, Anderson JA: Fertility and perinatal/postnatal studies in rats with the angiotensin-converting enzyme inhibitor, quinapril. Fundam Appl Toxicol 17: 684-695, 1991
43. Cozens DD, Barton SJ, Clark R, Hughes CW, Offer JM, Yamamoto Y: Reproductive toxicity studies of rentiapril. Arz Forsch/Drug Res 37: 164-169, 1987
44. Robertson RT, Minsker DH, Bokelman DL: MK-421 (enalapril maleate): Late gestation and lactation study in rats. Jpn Phamacol Ther 14: 43-55, 1986
45. McEvoy GK, Litvak K, Welsh OH Jr: In: American Hospital Formulatory Service. Drug Information. Published by the American Society of Health- System Pharmacists, Inc. Bethesda, MD, 1996, pp. 1128-1136 and 1144-1153
46. Guest I, Buttar HS, Smith S, Varma DR: Evaluation of the rat embryo culture system as a predictive test for human teratogens. Can J Physiol Pharmacol 72: 57-62, 1994
47. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321: 868-873, 1989
48. Sweet CS, Gross DM, Arbegast PT, Gaul SL, Britt PM, Ludden CT, Wietz D, Stone CA: Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl)]-L-Ala-L-Pro(MK-0421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther 216: 558-566, 1981
49. DiNicolantonio R: Failure of captopril to lower blood pressure in spontaneously hypertensive rats offered water and saline. Clin Exp Pharmacol Physiol 10: 269-272, 1983
50. Grossman A, Eckland D, Price P, Edwards CRW: Captopril: reversible renal failure with severe hyperkalemia. Lancet 1: 712, 1980
51. Dzau VJ, Gibbons GH, Pratt RE: Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 18: (Suppl. 2) 100-105, 1991
52. Le Noble FAC, Hekking JWM, Van Straaten HWM, Slaaf DW, Struyker-Boudier HAJ: Angiotensin II stimulates angiogenesis in the chorioallantoic membrane of the chick Embryo. Eur J Pharmacol 195: 305-306, 1991
53. Griendling KK, Lassegue B, Alexander RW: Angiotensin receptors and their therapeutic implications. Annul Rev Pharmacol Toxicol 36: 281-306, 1996
54. Kreft-Jais C, Plouin C, Tchobroutsky C, Boutroy MJ: Angiotensin-converting enzyme inhibitors during pregnancy: A survey of 22 patients given captopril and nine given enalapril. Br J Obstet Gynaecol 95: 420-422, 1988
55. Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 4th ed. Williams and Wilkins, Baltimore, 1994, pp. 120c-126c and 317e-324e
56. The WHO Working Group. Drugs and Human Lactation. PN Bennet (ed). Elsevier, New York, 1988, pp. 125-126
57. Committee on Drugs: American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 93: 137-150, 1994
58. Compendium of Pharmaceuticals and Specialties. Published by the Canadian Pharmaceutical Association, Ottawa, Canada, 1996